Pharmacogenetic study to predicting clinical response of oxaliplatin in patients with advanced colorectal cancer

不同患者对奥沙利铂诱导的神经病变的易感性差异很大。在这项研究中，我们研究了奥沙利铂诱导的神经病变与以下多态性之间的关系：谷胱甘肽s -转移酶p (GSTP1) Ile^<105>Val, glyoxylate aminotransferase (AGXT) Pro^<11>Leu和AGXT Ile^<340>Met。研究纳入了82名组织学证实的日本结直肠癌患者，他们接受了至少6个周期的改良FOLFOX6 （m-FOLFOX6）方案。2/3级神经病变组中携带GSTP1^<105>Val等位基因的患者多于1级神经病变组，但差异无统计学意义（41% vs 24%， P=0.098）。2/3级神经病组和1级神经病组中携带至少一个AGXT^<105>Met等位基因的患者数量相似（16% vs 13%； P=0.725）。在我们的患者和对照组中未发现AGXT^<11>Leu等位基因。

Susceptibility to oxaliplatin-induced neuropathy differs greatly among patients. In this study, we investigated the associations between oxaliplatin-induced neuropathy and the following polymorphisms : glutathione S-transferase p (GSTP1) Ile^<105>Val, and glyoxylate aminotransferase (AGXT) Pro^<11>Leu and AGXT Ile^<340>Met. Eighty-two Japanese patients with histologically confirmed colorectal cancer who received at least six cycles of the modified FOLFOX6 (m-FOLFOX6) regimen were enrolled.There were more patients carrying at least one GSTP1^<105>Val allele among the group with grade 2/3 neuropathy han among the group with grade 1 neuropathy although the difference was not statistically significant (41% vs 24%, P=0.098). There were similar numbers of patients carrying at least one AGXT^<105>Met allele in the grade 2/3 neuropathy and grade 1 neuropathy groups (16% vs 13% ; P=0.725). The AGXT^<11>Leu allele was not found in any of our patients or controls.